Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Allergen-specific immune tolerance induction is a therapeutic immunological process used primarily to treat allergic diseases (such as allergic rhinitis, asthma, and food allergy)[1][3][5]. The process is achieved through repeated administration of small, controlled doses of allergen, leading to the expansion of regulatory T cells (particularly Foxp3^+^ CD4^+^CD25^+^ Treg cells) and the production of regulatory cytokines (IL-10, TGF-β). These mediators suppress the function of allergen-specific effector T cells, reduce production of IgE (the key antibody in allergic reactions), and promote the generation of "blocking" IgG4 antibodies that compete with IgE for allergen binding, thus inhibiting mast cell and basophil activation. Tolerogenic dendritic cells also play an important role in driving Treg expansion and differentiation. Effective induction of immune tolerance is measured by increased IgG4, decreased IgE, increased regulatory cell populations, and reduced allergic inflammation[1][3][2][4][5]. This target name refers to a mechanism rather than a druggable molecular entity; any pharmacological intervention aiming to induce allergen-specific tolerance will typically involve multiple molecular and cellular pathways. Therefore, "Allergen-specific immune tolerance induction" is not a canonical drug target but describes a complex multi-component therapeutic outcome[1][3].
Expansion and activation of regulatory T cells (Tregs); Induction of tolerogenic dendritic cells[2][4]; Increased secretion of regulatory cytokines (IL-10, TGF-β, IL-35)[1][3][4]; Suppression of allergen-specific Th2 and Th1 effector cells[1][3]; Blockade of mast cell, eosinophil, and basophil activation[1]; Induction of "blocking" IgG4 antibodies that prevent allergen-IgE mediated activation[1][3]; Promotion of T cell anergy and deletion of autoreactive T cells[2][4]
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Allergen-specific immune tolerance induction.